Investigational Drug Information for Rivoglitazone
✉ Email this page to a colleague
What is the development status for investigational drug Rivoglitazone?
Rivoglitazone is an investigational drug.
There have been 5 clinical trials for Rivoglitazone.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 23rd 2007.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and [disabled in preview]. The leading clinical trial sponsors are Daiichi Sankyo Inc., Daiichi Sankyo, Inc., and Daiichi Sankyo Co., Ltd.
Summary for Rivoglitazone
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,086 |
| WIPO Patent Applications | 646 |
| Japanese Patent Applications | 95 |
| Clinical Trial Progress | Phase 3 (2007-04-23) |
| Vendors | 23 |
Recent Clinical Trials for Rivoglitazone
| Title | Sponsor | Phase |
|---|---|---|
| Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus | Daiichi Sankyo Inc. | Phase 3 |
| Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus | Daiichi Sankyo, Inc. | Phase 3 |
| Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 Diabetes | Daiichi Sankyo Co., Ltd. | Phase 2 |
Clinical Trial Summary for Rivoglitazone
Top disease conditions for Rivoglitazone
Top clinical trial sponsors for Rivoglitazone
US Patents for Rivoglitazone
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
